The University of Southampton
University of Southampton Institutional Repository

KIR2DS2 expression identifies NK cells with enhanced anticancer activity

KIR2DS2 expression identifies NK cells with enhanced anticancer activity
KIR2DS2 expression identifies NK cells with enhanced anticancer activity
NK cells are promising cellular therapeutics against hematological and solid malignancies. Immunogenetic studies have identified that various activating killer cell Ig-like receptors (KIRs) are associated with cancer outcomes. Specifically, KIR2DS2 has been associated with reduced incidence of relapse following transplant in hematological malignancies and improved outcomes in solid tumors, but the mechanism remains obscure. Therefore, we investigated how KIR2DS2 expression impacts NK cell function. Using a novel flow cytometry panel, we show that human NK cells with high KIR2DS2 expression have enhanced spontaneous activation against malignant B cell lines, liver cancer cell lines, and primary chronic lymphocytic leukemia cells. Surface expression of CD16 was increased on KIR2DS2high NK cells, and, accordingly, KIR2DS2high NK cells had increased activation against lymphoma cells coated with the clinically relevant anti-CD20 Abs rituximab and obinutuzumab. Bulk RNA sequencing revealed that KIR2DS2high NK cells have upregulation of NK-mediated cytotoxicity, translation, and FCGR gene pathways. We developed a novel single-cell RNA-sequencing technique to identify KIR2DS2+ NK cells, and this confirmed that KIR2DS2 is associated with enhanced NK cell–mediated cytotoxicity. This study provides evidence that KIR2DS2 marks a population of NK cells primed for anticancer activity and indicates that KIR2DS2 is an attractive target for NK-based therapeutic strategies.
0022-1767
379-390
Blunt, Matthew
b1109de3-6045-4bc3-bd77-6cf26504697d
Cragg, Mark
ec97f80e-f3c8-49b7-a960-20dff648b78c
Doyle, Amber
eff9eb33-8e3e-4597-9ef1-7b1015a5f343
Fisher, Jack, Graham
5d9176a9-c6a6-4234-a178-3054eee07eb4
Khakoo, Salim
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Polak, Marta Ewa
bf81bccc-6e22-4182-beed-ccf2fdbc9f8c
Graham, Lara, Victoria
4a7bbe46-4e8e-476d-87f5-5c83304a5293
Vallejo Pulido, Andres
27bc0b94-0c40-4fd1-9533-7e267d588c0a
Fulton, Rebecca
848aa9dc-797f-40f8-b63d-bca0d90f7b55
Carter, Matthew
3baac102-d80c-42ba-ab4d-ad339a48169e
Blunt, Matthew
b1109de3-6045-4bc3-bd77-6cf26504697d
Cragg, Mark
ec97f80e-f3c8-49b7-a960-20dff648b78c
Doyle, Amber
eff9eb33-8e3e-4597-9ef1-7b1015a5f343
Fisher, Jack, Graham
5d9176a9-c6a6-4234-a178-3054eee07eb4
Khakoo, Salim
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Polak, Marta Ewa
bf81bccc-6e22-4182-beed-ccf2fdbc9f8c
Graham, Lara, Victoria
4a7bbe46-4e8e-476d-87f5-5c83304a5293
Vallejo Pulido, Andres
27bc0b94-0c40-4fd1-9533-7e267d588c0a
Fulton, Rebecca
848aa9dc-797f-40f8-b63d-bca0d90f7b55
Carter, Matthew
3baac102-d80c-42ba-ab4d-ad339a48169e

Blunt, Matthew, Cragg, Mark, Doyle, Amber, Fisher, Jack, Graham, Khakoo, Salim, Forconi, Francesco, Johnson, Peter, Polak, Marta Ewa, Graham, Lara, Victoria, Vallejo Pulido, Andres, Fulton, Rebecca and Carter, Matthew (2022) KIR2DS2 expression identifies NK cells with enhanced anticancer activity. The Journal of Immunology, 209 (2) (2), 379-390. (doi:10.4049/jimmunol.2101139).

Record type: Article

Abstract

NK cells are promising cellular therapeutics against hematological and solid malignancies. Immunogenetic studies have identified that various activating killer cell Ig-like receptors (KIRs) are associated with cancer outcomes. Specifically, KIR2DS2 has been associated with reduced incidence of relapse following transplant in hematological malignancies and improved outcomes in solid tumors, but the mechanism remains obscure. Therefore, we investigated how KIR2DS2 expression impacts NK cell function. Using a novel flow cytometry panel, we show that human NK cells with high KIR2DS2 expression have enhanced spontaneous activation against malignant B cell lines, liver cancer cell lines, and primary chronic lymphocytic leukemia cells. Surface expression of CD16 was increased on KIR2DS2high NK cells, and, accordingly, KIR2DS2high NK cells had increased activation against lymphoma cells coated with the clinically relevant anti-CD20 Abs rituximab and obinutuzumab. Bulk RNA sequencing revealed that KIR2DS2high NK cells have upregulation of NK-mediated cytotoxicity, translation, and FCGR gene pathways. We developed a novel single-cell RNA-sequencing technique to identify KIR2DS2+ NK cells, and this confirmed that KIR2DS2 is associated with enhanced NK cell–mediated cytotoxicity. This study provides evidence that KIR2DS2 marks a population of NK cells primed for anticancer activity and indicates that KIR2DS2 is an attractive target for NK-based therapeutic strategies.

Text
379.full - Version of Record
Available under License Creative Commons Attribution.
Download (2MB)

More information

Accepted/In Press date: 8 May 2022
Published date: 15 July 2022
Additional Information: Funding Information: This work was supported by a John Goldman Fellowship from Leukaemia UK to M.D.B. and grants from the Medical Research Council (519241101) and Cancer Research UK consortium “HUNTER” to S.I.K. The 10X Chromium Controller was funded by a Cancer Research UK Advanced Clinician Scientist Fellowship to Sean Hua Lim (A27179). Publisher Copyright: © 2022 TheAuthors.

Identifiers

Local EPrints ID: 468430
URI: http://eprints.soton.ac.uk/id/eprint/468430
ISSN: 0022-1767
PURE UUID: 206a9b5f-8852-4337-8a22-bbe1e3b68f5e
ORCID for Matthew Blunt: ORCID iD orcid.org/0000-0003-1099-3985
ORCID for Mark Cragg: ORCID iD orcid.org/0000-0003-2077-089X
ORCID for Jack, Graham Fisher: ORCID iD orcid.org/0000-0002-5090-7503
ORCID for Salim Khakoo: ORCID iD orcid.org/0000-0002-4057-9091
ORCID for Francesco Forconi: ORCID iD orcid.org/0000-0002-2211-1831
ORCID for Peter Johnson: ORCID iD orcid.org/0000-0003-2306-4974
ORCID for Andres Vallejo Pulido: ORCID iD orcid.org/0000-0002-4688-0598

Catalogue record

Date deposited: 15 Aug 2022 16:40
Last modified: 17 Mar 2024 04:04

Export record

Altmetrics

Contributors

Author: Matthew Blunt ORCID iD
Author: Mark Cragg ORCID iD
Author: Amber Doyle
Author: Jack, Graham Fisher ORCID iD
Author: Salim Khakoo ORCID iD
Author: Peter Johnson ORCID iD
Author: Marta Ewa Polak
Author: Lara, Victoria Graham
Author: Andres Vallejo Pulido ORCID iD
Author: Rebecca Fulton
Author: Matthew Carter

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×